Can liraglutide and metformin be taken together?

Yes. This is a commonly prescribed combination for type 2 diabetes, supported by clinical trial evidence. Both drugs work through different mechanisms to lower blood sugar.

Does this combination increase hypoglycemia risk?

The combination itself has a low risk of hypoglycemia. Risk increases substantially if insulin or a sulfonylurea is added.

Is there a drug interaction between liraglutide and metformin?

There is no pharmacokinetic interaction. The combination is additive for glucose lowering and generally well tolerated.

What should I watch for when taking both?

Monitor for gastrointestinal side effects especially early in liraglutide therapy. Also monitor kidney function, which is required for safe metformin use.

Liraglutide & Metformin Interaction

Minor

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Learn more about Liraglutide →Learn more about Metformin →

Overview

Liraglutide (a GLP-1 receptor agonist) and metformin are a well-established combination for type 2 diabetes. Both drugs lower blood glucose by complementary mechanisms and can be used together safely. The combination was evaluated in multiple LEAD clinical trials showing additive efficacy.

How does this interaction occur?

Liraglutide activates GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. Metformin reduces hepatic glucose output and enhances peripheral insulin sensitivity via AMPK activation. These distinct mechanisms act synergistically without markedly increasing hypoglycemia risk.

Clinical significance

The LEAD-2 trial demonstrated that liraglutide added to metformin significantly reduced HbA1c and body weight compared to metformin alone or metformin plus glimepiride. GI side effects are common during initiation but typically resolve. Cardiovascular benefits of liraglutide (LEADER trial) are maintained in the context of metformin co-administration.

Management recommendations

Initiate liraglutide at 0.6 mg/day SC and escalate weekly per label. Metformin dose does not require adjustment. Counsel on GI side effects during escalation. Ensure adequate hydration. Renal function should be monitored for metformin safety.

What to monitor

HbA1c at 3-month intervals until stable. Renal function annually or per metformin labeling. Body weight and cardiovascular risk factors. Report persistent nausea, vomiting, or abdominal pain.

Alternative options

Alternatives include liraglutide with an SGLT-2 inhibitor, or substitution with another GLP-1 agonist (e.g., semaglutide) if GI tolerability is an issue.

Frequently asked questions

References

[Regulatory] Liraglutide (Victoza) FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf Accessed 2026-03-01.
[Regulatory] Nauck M et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin. Diabetes Care 2009. https://pubmed.ncbi.nlm.nih.gov/19174464/ Accessed 2026-03-01.
[Regulatory] LEADER Trial: Liraglutide and Cardiovascular Outcomes. NEJM 2016. https://www.nejm.org/doi/10.1056/NEJMoa1603827 Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026